COMMETS- Combination MCI Metabolic Syndrome

NCT06072963 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease
Mild Cognitive Impairment
Metabolic Syndrome

Interventions

DRUG: Semaglutide
DRUG: Intranasal insulin
OTHER: Semaglutide placebo
OTHER: Intranasal insulin placebo

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]